.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Phillygenin (PHI), a key bioactive ligand from Forsythia suspensa, is gaining recognition for its therapeutic potential. While traditional medicine often highlights its antiviral and antioxidant properties, robust toxicological data were previously limited. A recent systematic evaluation now clarifies the Phillygenin safety profile, showing that this compound possesses a wide margin of safety for oral administration. Researchers assessed its safety through both acute and sub-chronic assays to provide essential evidence for clinical applications.
The study conducted toxicity tests following strict international guidelines to ensure reliable results. In the acute phase, KM mice received a single high dose of 5000 mg/kg body weight. Consequently, researchers observed no treatment-related mortality or toxic manifestations over 14 days, indicating a lethal dose (LD50) exceeding 5000 mg/kg. Furthermore, a 28-day sub-chronic study evaluated doses reaching 25,000 mg/kg in SD mice. Across all groups, clinical signs, body weight, and biochemical parameters remained normal. Additionally, histopathological examinations revealed no damage to vital organs.
Beyond its safety, Phillygenin significantly improves liver health by boosting essential antioxidant defenses. The research demonstrated that PHI increases levels of Superoxide Dismutase (SOD) and Glutathione (GSH) in the liver. Simultaneously, it reduces Malondialdehyde (MDA), which is a common marker of oxidative stress. Moreover, Phillygenin suppressed the expression of Pregnane X Receptor (PXR) and the enzyme CYP3A1. This finding suggests that the compound can effectively modulate xenobiotic metabolism. Collectively, these results support the development of PHI as a safe agent for hepatoprotective and antiviral therapies.
Phillygenin is a natural bioactive ligand extracted from the plant Forsythia suspensa, widely used for its antioxidant and antiviral properties.
Yes, recent toxicological studies show a high safety margin with an LD50 exceeding 5000 mg/kg and no adverse effects during long-term sub-chronic administration.
It enhances the liver\'s antioxidant capacity by increasing SOD and GSH levels while reducing oxidative damage and modulating drug-metabolizing enzymes.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Qian J et al. Toxicological and Liver Antioxidant Evaluation of Phillygenin Following Acute and Sub-Chronic Oral Administration. J Appl Toxicol. 2026 May 06. doi: 10.1002/jat.70224. PMID: 42092304.
2. Zhou Y et al. Phillygenin: A review of its pharmacology, pharmacokinetics, and safety. Phytomedicine. 2022;104:154316.
3. Guo H et al. Antiviral and anti-inflammatory activities of Phillygenin from Forsythia suspensa. J Ethnopharmacol. 2022;284:114812.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New toxicological data confirms Phillygenin's high safety margin and its ability to enhance liver antioxidant capacity and modulate xenobiotic metabolism....
4 months ago
A comparative analysis shows that older age, elevated blood glucose, and abdominal adiposity are primary drivers of hypertension. Comprehensive evaluation of cardiometabolic risk profiles enables clinicians to detect overlapping metabolic dysfunctions early and optimize targeted prevention strategies.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Left ventricular thrombus is a severe complication of acute decompensated heart failure. This clinical review explores the pathophysiology, imaging challenges, and pharmacotherapeutic considerations of laminated thrombi, evaluating the evolving role of direct oral anticoagulants versus traditional warfarin.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
